Vitality Watch

Dossier clinicaltrials observational 10-nov-2026
Human cohort, case-control, or epidemiological association

PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty

Key claim: Postprandial secretion of the gut-derived hormone FGF-19 is proposed as a potential regulator and biomarker of skeletal muscle maintenance in older adults with frailty and sarcopenia.

Abstract

Fibroblast Growth Factor 19 (FGF-19) is an intestinal hormone secreted in the post-prandial state, whose primary role is to inhibit bile acid synthesis in the liver. It is expressed by the FXR (Farnesoid X receptor) nuclear receptor in the enterocytes of the ileum, which is activated by specific bile acids metabolized in the gut microbiota. It was demonstrated that treatment with FGF-19 induces myofiber hypertrophy in vitro and increases muscle strength and mass in mice model of sarcopenia. Sarcopenia and the commonly associated physical frailty, are age-related syndromes associated with adverse events (such as falls and fractures, mobility disability) and increased mortality. Currently, there is no drug treatment that has been proven effective to counteract those syndromes and standard care consists in non-pharmacological interventions (exercise and nutrition) whose implementation remains complex due to several barriers. Moreover, the anabolic resistance underlying sarcopenia hampers the exercise-induced response on muscle mass and the level of evidence for this outcome remains poor-to-moderate. Thus, FGF-19 could be considered as a new regulator of skeletal muscle in elderly living with sarcopenia/frailty but there are, to date, only few data available in the literature. First and foremost, it is crucial to understand the relationship between postprandial FGF-19 and muscle which has not been characterized yet.

Why this matters

The human-observational study description brings postprandial FGF-19 profiling into the investigation of frailty, but supplies no results establishing an association or biomarker performance [human-observational]. Its proposed role in skeletal muscle maintenance remains a mechanistic hypothesis rather than evidence that manipulating this pathway preserves muscle in humans [mechanism-plausible].

Source

Link

Briefing card

PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty
Stage: observational · clinicaltrials · 10-nov-2026

Postprandial secretion of the gut-derived hormone FGF-19 is proposed as a potential regulator and biomarker of skeletal muscle maintenance in older adults with frailty and sarcopenia.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07893665

build build 880 · 2bcef25 · 2026-11-18